Site notifications

Sub menu

 

 

Australian Nuclear Science and Technology Organisation (ANSTO)

Regulatory activities for this sponsor.

Type

Date

2 result(s) found, displaying 1 to 2

  • AusPAR: Lutetium (177Lu) chloride

    Australian public assessment report (AusPar)
    AusPAR for Lutetium (177Lu) chloride (lutetium (177Lu) chloride) for the treatment of non-resectable or metastatic neuroendocrine tumours expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule.

  • Lutetium (177Lu) Chloride

    Prescription medicine decision summary
    ANSTO Lutetium (177Lu) chloride (lutetium (177 Lu) chloride) is approved to treat non resectable or metastatic neuroendocrine tumours.